AU2019287659B2 - Glycosylated ComP pilin variants, methods of making and uses thereof - Google Patents

Glycosylated ComP pilin variants, methods of making and uses thereof Download PDF

Info

Publication number
AU2019287659B2
AU2019287659B2 AU2019287659A AU2019287659A AU2019287659B2 AU 2019287659 B2 AU2019287659 B2 AU 2019287659B2 AU 2019287659 A AU2019287659 A AU 2019287659A AU 2019287659 A AU2019287659 A AU 2019287659A AU 2019287659 B2 AU2019287659 B2 AU 2019287659B2
Authority
AU
Australia
Prior art keywords
seq
comp
amino acid
protein
polysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019287659A
Other languages
English (en)
Other versions
AU2019287659A1 (en
Inventor
Mario Feldman
Christian HARDING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxnewmo LLC
Original Assignee
Vaxnewmo LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxnewmo LLC filed Critical Vaxnewmo LLC
Publication of AU2019287659A1 publication Critical patent/AU2019287659A1/en
Application granted granted Critical
Publication of AU2019287659B2 publication Critical patent/AU2019287659B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2019287659A 2018-06-16 2019-06-14 Glycosylated ComP pilin variants, methods of making and uses thereof Active AU2019287659B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862685970P 2018-06-16 2018-06-16
US62/685,970 2018-06-16
US201862783971P 2018-12-21 2018-12-21
US62/783,971 2018-12-21
PCT/US2019/037251 WO2019241672A2 (en) 2018-06-16 2019-06-14 Glycosylated comp pilin variants, methods of making and uses thereof

Publications (2)

Publication Number Publication Date
AU2019287659A1 AU2019287659A1 (en) 2021-01-07
AU2019287659B2 true AU2019287659B2 (en) 2025-02-20

Family

ID=68843212

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019287659A Active AU2019287659B2 (en) 2018-06-16 2019-06-14 Glycosylated ComP pilin variants, methods of making and uses thereof

Country Status (7)

Country Link
US (2) US11932670B2 (enExample)
EP (1) EP3806881B1 (enExample)
JP (2) JP2021528059A (enExample)
AU (1) AU2019287659B2 (enExample)
CA (1) CA3103474A1 (enExample)
ES (1) ES3051337T3 (enExample)
WO (1) WO2019241672A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265391B2 (en) 2015-02-26 2019-04-23 Vaxnewmo Llc Acinetobacter O-oligosaccharyltransferases and uses thereof
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CA3103474A1 (en) 2018-06-16 2019-12-19 Vaxnewmo Llc Glycosylated comp pilin variants, methods of making and uses thereof
WO2020131236A1 (en) * 2018-12-21 2020-06-25 Vaxnewmo Llc O-linked glycosylation recognition motifs
BR112022023234A2 (pt) * 2020-06-25 2023-01-03 Glaxosmithkline Biologicals Sa Proteínas de exotoxina a modificada
WO2022147142A1 (en) * 2020-12-31 2022-07-07 Vaxnewmo Llc Klebsiella pneumoniae o-antigen glycosylated proteins and methods of making and uses thereof
WO2022232256A1 (en) * 2021-04-28 2022-11-03 Vaxnewmo Llc Minimal sequons sufficient for o-linking glycosylation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016134485A1 (en) * 2015-02-26 2016-09-01 Vaxalta Inc. Acinetobacter o-oligosaccharyltransferases and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010515430A (ja) 2006-12-13 2010-05-13 ザ・ガバナーズ・オブ・ザ・ユニバーシティ・オブ・アルバータ タンパク質のｏ−グリコシル化方法およびそのシステム
WO2011109600A1 (en) 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
CA2844831A1 (en) 2011-08-12 2013-02-21 The Governors Of The University Of Alberta Method of diagnosing bacterial infections using bacterial glycoproteins
HK1202896A1 (en) 2011-11-04 2015-10-09 康奈尔大学 A prokaryote-based cell-free system for the synthesis of glycoproteins
ES2905107T3 (es) 2012-10-12 2022-04-07 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras
EP3444352B1 (en) * 2012-11-07 2020-12-16 GlaxoSmithKline Biologicals SA Production of recombinant vaccine in e. coli by enzymatic conjugation
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
JP6356229B2 (ja) 2013-06-04 2018-07-11 アイコン ジェネティクス ゲーエムベーハー 植物産生糖タンパク質及び組換え糖タンパク質のｎ−グリコシル化部位占有率を調節する方法
EP3193918A4 (en) 2014-09-18 2018-06-20 University of Maryland, Baltimore Broad spectrum conjugate vaccine to prevent klebsiella pneumoniae and pseudomonas aeruginosa infections
DK3240895T3 (da) 2014-12-30 2022-04-11 Glaxosmithkline Biologicals Sa Sammensætninger og fremgangsmåder til proteinglykosylering
JP6968451B2 (ja) 2017-01-17 2021-11-17 バイオアプリケーションズ インコーポレイテッドBioapplications Inc. 植物細胞における目的タンパク質の発現のための組換えベクター
EP3492481A1 (en) 2017-11-30 2019-06-05 Vaxxilon AG Vaccine against klebsiella pneumoniae
CA3103474A1 (en) 2018-06-16 2019-12-19 Vaxnewmo Llc Glycosylated comp pilin variants, methods of making and uses thereof
US20220054632A1 (en) 2018-12-12 2022-02-24 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
WO2020131236A1 (en) 2018-12-21 2020-06-25 Vaxnewmo Llc O-linked glycosylation recognition motifs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016134485A1 (en) * 2015-02-26 2016-09-01 Vaxalta Inc. Acinetobacter o-oligosaccharyltransferases and uses thereof

Also Published As

Publication number Publication date
JP2021528059A (ja) 2021-10-21
WO2019241672A3 (en) 2020-02-06
US20210324017A1 (en) 2021-10-21
EP3806881A2 (en) 2021-04-21
JP2024079845A (ja) 2024-06-11
US12577280B2 (en) 2026-03-17
CA3103474A1 (en) 2019-12-19
EP3806881A4 (en) 2022-07-27
AU2019287659A1 (en) 2021-01-07
US11932670B2 (en) 2024-03-19
US20240262870A1 (en) 2024-08-08
WO2019241672A2 (en) 2019-12-19
ES3051337T3 (en) 2025-12-26
EP3806881B1 (en) 2025-10-08

Similar Documents

Publication Publication Date Title
US12577280B2 (en) Glycosylated comp pilin variants, methods of making and uses thereof
US12350342B2 (en) O-linked glycosylation recognition motifs
WO2017067964A1 (en) P. aeruginosa pcrv-linked antigen vaccines
JP7551618B2 (ja) Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
JP2023531059A (ja) 肺炎桿菌ｏ抗原ワクチン
US20240066109A1 (en) Klebsiella Pneumoniae O-Antigen Glycosylated Proteins and Methods of Making and Uses Thereof
WO2024175620A1 (en) Immunogenic composition
US20240207383A1 (en) Minimal Sequons Sufficient for O-Linking Glycosylation
CN120897997A (zh) 用于生产具有与第二多肽配偶体的异肽键的糖缀合物多肽的组合物和方法以及这些糖缀合物多肽的用途
JP2025535072A (ja) モラクセラ科ｏ結合型オリゴ糖転移酵素、糖鎖付加断片、及びそれらの使用
Mayer et al. A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host
EP4452308A1 (en) Vaccine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)